Pediatrics

Q89. Discuss Micronutrient Deficiencies: Zinc, Iron, and Vitamin A, including clinical presentation and staging/prevention frameworks.

Zinc Deficiency

Acrodermatitis enteropathica is the classic, most severe manifestation of significant zinc deficiency — a distinctive periorificial and acral (hands, feet) dermatitis, often vesiculobullous or erosive, accompanied by alopecia and diarrhea, forming a recognizable clinical triad. This presentation may reflect either the rare genetic (autosomal recessive) form (mutations in zinc transporter gene SLC39A4) or, more commonly, acquired zinc deficiency from inadequate dietary intake, malabsorption, or increased losses (e.g., prolonged diarrheal illness, itself both a cause and consequence of zinc deficiency).

Vitamin A Deficiency – WHO Staging

Iron Deficiency Anemia – Prevention

Given iron deficiency's status as the most common global nutritional deficiency and its adverse impact on cognitive/neurodevelopmental outcomes, prevention strategies center on:

• Timely introduction of iron-rich complementary foods from 6 months of age
• Delayed cord clamping at birth (boosts neonatal iron stores)
• Routine iron supplementation programs, particularly in preterm/low birth weight infants (reduced iron stores, since most fetal iron accretion occurs in the third trimester) and in high-prevalence populations

Q90. Discuss Glycogen Storage Diseases (GSD) Types I, II, and III: enzymatic defects, clinical features, and management.

GSD Type I (Von Gierke Disease) – Detail

Deficiency of glucose-6-phosphatase, the final enzyme required for both glycogenolysis and gluconeogenesis, causes the most severe hypoglycemic phenotype among GSDs. The combination of hypoglycemia with lactic acidosis, hyperlipidemia, and hyperuricemia (rather than hypoglycemia in isolation) is a particularly characteristic, frequently-tested biochemical signature.

GSD Type II (Pompe Disease) – Detail

Deficiency of acid alpha-glucosidase, a lysosomal enzyme — distinguishing Pompe from the other GSDs, which primarily involve cytoplasmic defects. Pompe disease is more accurately understood as a lysosomal storage disorder presenting with the glycogen accumulation phenotype. Infantile-onset form is rapidly fatal without treatment, typically from cardiorespiratory failure. Enzyme Replacement Therapy (ERT) with recombinant alglucosidase alfa has transformed prognosis.

GSD Type III (Forbes-Cori Disease) – Detail

Deficiency of the glycogen debranching enzyme causes accumulation of abnormal, incompletely-degraded glycogen with short outer branches. Generally milder than GSD I since gluconeogenesis remains intact, providing residual glucose-generating capacity. Can distinctively involve skeletal and cardiac muscle (particularly GSD IIIa subtype), helping distinguish it from the purely hepatic pattern of Type I.

Q91. Discuss Phenylketonuria (PKU) and Hyperphenylalaninemia, including newborn screening, dietary management, and the BH4-deficiency variant.

Pathophysiology

Classic PKU results from deficiency of phenylalanine hydroxylase, the hepatic enzyme converting phenylalanine to tyrosine. Deficiency causes accumulation of phenylalanine (and, to a lesser extent, phenylketones via a minor alternative pathway, giving the condition its name), exerting direct neurotoxic effects — interfering with amino acid transport across the blood-brain barrier and normal myelination. If untreated, this produces progressive, severe, irreversible intellectual disability, plus a characteristic "musty" body odor, eczema, and relative hypopigmentation (fair skin, light hair, given tyrosine's role as melanin precursor).

Newborn Screening

PKU is the historical prototype for population-based newborn screening (originally the Guthrie bacterial inhibition assay, now largely superseded), and remains a cornerstone of virtually all contemporary newborn screening programs, performed via tandem mass spectrometry (MS/MS). It exemplifies the ideal screening-candidate condition: a severe, otherwise entirely preventable outcome that can be completely averted through early identification and dietary intervention before the child becomes symptomatic.

Clinical Presentation (Without Screening/Treatment)

Progressive developmental delay/intellectual disability over the first months to years, seizures, behavioral disturbance (hyperactivity, autism-spectrum-like features), the characteristic musty odor, hypopigmentation, and eczematous skin changes.

Dietary Management

Lifelong dietary phenylalanine restriction, carefully titrated to maintain blood phenylalanine within a defined therapeutic range (avoiding both neurotoxicity and, since phenylalanine remains essential, deficiency). Phenylalanine-free/very-low-phenylalanine medical formulas provide the majority of protein/amino acid requirements, supplemented with measured amounts of natural phenylalanine-containing foods for minimum essential growth needs, with regular blood monitoring guiding adjustment.

BH4 (Tetrahydrobiopterin) Deficiency – An Important Distinct Category

A minority of infants with elevated phenylalanine on newborn screening have a defect in synthesis/recycling of BH4, an essential cofactor for phenylalanine hydroxylase (and also tyrosine hydroxylase and tryptophan hydroxylase, needed for dopamine and serotonin synthesis). BH4-deficient infants, unlike classic PKU, develop progressive neurological deterioration despite adequate dietary phenylalanine control, given the cofactor's additional impact on neurotransmitter synthesis.

Routine screening for BH4 deficiency (urine pterin analysis and/or BH4 loading test) is essential in every infant with hyperphenylalaninemia on newborn screening. Treatment requires BH4 (sapropterin) supplementation plus specific neurotransmitter precursor replacement (L-dopa and 5-hydroxytryptophan).

Q92. Discuss Infant and Young Child Feeding (IYCF) Guidelines: exclusive breastfeeding, complementary feeding, and responsive feeding.

Exclusive Breastfeeding

Current WHO and national guidance recommends exclusive breastfeeding for the first 6 months of life (breast milk only, no other liquids or foods, not even water, except medically indicated medications/vitamin-mineral supplements) — breast milk alone is nutritionally sufficient for a healthy term infant through this period, alongside its immunological, developmental, and maternal health benefits. Initiation within the first hour of life is also specifically emphasized, facilitating early lactation establishment and colostrum provision (rich in immunoglobulins/protective factors).

Complementary Feeding Introduction

Timing

Complementary foods introduced starting at 6 months, alongside continued breastfeeding (ideally through 2 years of age or beyond). Too early risks displacing breast milk and exceeding gut/renal maturity; too late risks inadequate nutrient provision (particularly iron and zinc) and impaired oral-motor skill development.

Density and Frequency

Foods should be energy and nutrient-dense (not excessively diluted/watery). Feeding frequency increases with age:

• 6–8 months: 2–3 meals/day
• 9–24 months: 3–4 meals/day plus 1–2 nutritious snacks

Consistency Progression

• 6 months: thick, pureed/mashed foods
• 8–9 months: minced/chopped textures
• 12 months: family/table foods (appropriately modified to minimize choking risk)

Responsive Feeding

A key, increasingly emphasized principle of contemporary IYCF guidance — feeding practices attentive and responsive to the child's hunger and satiety cues, rather than rigid schedules or pressured/forced feeding. Involves active encouragement while respecting autonomy and self-regulation, patience during developing feeding-skill acquisition, minimizing distractions, and consistent, encouraging (not coercive) interactions — supporting both adequate nutrient intake and healthy, self-regulated long-term eating behaviors.

Q93. Discuss the Mucopolysaccharidoses (MPS), including shared pathophysiology, common clinical/radiological features, and specific subtypes (Hurler, Hunter, Morquio).

Shared Pathophysiological Mechanism

The MPS group are lysosomal storage disorders, each caused by deficiency of a specific enzyme required for stepwise degradation of glycosaminoglycans (GAGs, previously "mucopolysaccharides") — normal, essential connective tissue components. Enzyme deficiency causes progressive intracellular/intralysosomal accumulation of partially-degraded GAG fragments across multiple tissues, producing the characteristic multisystem, progressive clinical phenotype.

Clinical Phenotype (Common Features)

• Coarse facial features (becoming progressively apparent over the first years of life)
• Hepatosplenomegaly
• Joint stiffness/contractures (with joint laxity in other specific joints in some subtypes)
• Corneal clouding (present in some but not all subtypes)
• Short stature
• Progressive neurological/cognitive decline in several subtypes

Radiological Features – Dysostosis Multiplex

A characteristic, shared skeletal pattern: thickened, oar-shaped ribs; J-shaped or hook-shaped (beaked) vertebral bodies; wide, irregular metacarpals with proximal pointing; and thickened calvarium.

Specific Subtypes

Enzyme Replacement Therapy (ERT)

A major, transformative therapeutic advance for several subtypes: laronidase (MPS I), idursulfase (MPS II), elosulfase alfa (MPS IVA). ERT reduces ongoing GAG accumulation in peripheral tissues, improving organomegaly, joint mobility, pulmonary function, and growth — but does not effectively cross the blood-brain barrier, providing limited/no benefit for CNS manifestations. Hematopoietic stem cell transplantation remains the preferred approach for severe Hurler syndrome when performed early, before significant irreversible neurological injury.

Q94. Discuss Wilson Disease: pathophysiology, clinical presentation, diagnosis, and treatment.

Pathophysiology of Copper Metabolism Defect

Autosomal recessive disorder caused by mutations in ATP7B, encoding a copper-transporting P-type ATPase expressed predominantly in hepatocytes. This transporter (1) transports copper into the secretory pathway for incorporation into ceruloplasmin, and (2) mediates biliary excretion of excess copper, the primary route of copper elimination. Loss of function causes a combined defect: impaired ceruloplasmin synthesis (explaining characteristically low serum ceruloplasmin) AND impaired biliary copper excretion (the more fundamentally important defect), causing progressive copper accumulation — initially hepatotoxic within the liver, then "spilling over" into extrahepatic tissues, most significantly the brain (basal ganglia) and cornea.

Clinical Presentation

Hepatic Presentation

Typically the earlier-presenting manifestation, particularly in children — ranging from asymptomatic transaminase elevation, through chronic hepatitis, to cirrhosis, and in a subset, acute (fulminant) liver failure.

Neuropsychiatric Presentation

Typically emerges later, once hepatic storage capacity is exceeded — movement disorder features (tremor, dystonia, choreoathetosis, parkinsonism-like rigidity/bradykinesia, characteristic dysarthria), and psychiatric manifestations (personality change, declining performance, depression, occasionally psychotic features).

Kayser-Fleischer (KF) Rings

The classic, most specific sign — copper deposition in Descemet's membrane, a golden-brown to greenish ring at the corneal periphery, best seen on slit-lamp examination. Highly specific but not fully sensitive (present in the great majority with neurological manifestations, but fewer with purely hepatic presentation). Absence of KF rings does NOT exclude Wilson disease.

Diagnostic Workup

• Serum ceruloplasmin — typically low, but an acute-phase reactant that can be falsely elevated with inflammation; a minority of true patients have normal levels
• 24-hour urinary copper excretion — typically markedly elevated; also useful for monitoring treatment response
• Slit-lamp examination for KF rings
• Liver biopsy with quantitative hepatic copper — the most definitive test when diagnosis remains uncertain
• Genetic testing for ATP7B mutations — for diagnostic confirmation and family/sibling screening

Treatment

Dietary Measures

Avoidance of high-copper foods (organ meats, shellfish, nuts, chocolate, mushrooms) is a sensible adjunct, but never sufficient as standalone therapy — must always be combined with pharmacological treatment.

Q95. Discuss Mitochondrial Disorders in Pediatrics: inheritance pattern, classic named syndromes, diagnosis, and management.

Mitochondrial Inheritance

A genuinely distinctive pattern: mitochondrial DNA (mtDNA) is inherited exclusively maternally (transmitted through the ovum's cytoplasm, negligible paternal contribution) — an affected mother transmits to all offspring, of either sex, while an affected father transmits to none. Heteroplasmy: cells contain many mitochondria/mtDNA copies, so a cell/tissue can contain a variable mixture of normal and mutant mtDNA, with the mutant proportion substantially influencing disease severity/organ pattern — explaining variable severity even among family members with the identical mutation.

Classic Named Syndromes

Diagnostic Workup

• Serum and CSF lactate — often elevated, but neither fully sensitive nor specific
• Muscle biopsy — histopathology (ragged red fibers) and biochemical respiratory chain enzyme complex activities
• Genetic testing — increasingly first-line, including mtDNA point mutations/deletions and nuclear gene panels/whole exome/genome sequencing

Management – "Mitochondrial Cocktail"

No curative or fundamentally disease-modifying therapy currently exists for most mitochondrial disorders; management remains predominantly supportive (seizure management, cardiac monitoring for cardiomyopathy, nutritional/growth support). The "mitochondrial cocktail" — Coenzyme Q10, L-carnitine, riboflavin, thiamine, and antioxidants (vitamin C and E) — is widely used empirically.

Q96. Discuss Organic Acidemias (Methylmalonic, Propionic, and Isovaleric Acidemia): presentation, diagnosis, and management.

Overview and Shared Presentation

Organic acidemias — Methylmalonic Acidemia (MMA), Propionic Acidemia (PA), and Isovaleric Acidemia (IVA) — result from defects in enzymes within the catabolic pathways for branched-chain amino acids (MMA and PA, both in the shared propionate metabolism pathway) or the leucine catabolic pathway (IVA). They follow the classic "intoxication type" clinical pattern: well at birth → symptom-free interval → progressive deterioration as toxic organic acid metabolites accumulate — poor feeding, vomiting, lethargy progressing to encephalopathy/coma.

Characteristic Laboratory Findings

• Significant metabolic acidosis with elevated anion gap
• Often accompanied hyperammonemia (secondary inhibition of the urea cycle by accumulated organic acid metabolites)
• Variably: hypoglycemia, ketosis
• Cytopenias (particularly neutropenia and thrombocytopenia) — a relatively distinctive additional feature of this group

Diagnostic Evaluation

• Urine organic acid analysis (GC-MS) — the key, definitive diagnostic test, identifying the specific pattern of abnormal metabolites
• Plasma acylcarnitine profile (tandem mass spectrometry) — complementary, often more rapidly available; basis for inclusion in expanded newborn screening panels

Acute Management

• Immediate cessation of protein intake
• High-calorie, protein-free IV glucose infusion to suppress catabolism
• Aggressive correction of metabolic acidosis (sometimes substantial sodium bicarbonate)
• Management of associated hyperammonemia (nitrogen scavenger therapy; hemodialysis for severe refractory cases)
• Specific cofactor trials: Vitamin B12/hydroxocobalamin (MMA subset), biotin (PA subset)
• L-carnitine supplementation — facilitates excretion of accumulated toxic acyl-CoA metabolites as acylcarnitine conjugates

Long-Term Management

Chronic dietary protein restriction (individualized), ongoing carnitine supplementation, careful "sick day" management protocols (proactive increased calories/reduced protein at first sign of intercurrent illness), and, for MMA specifically, monitoring for chronic kidney disease (a recognized long-term complication reflecting direct nephrotoxic effects of accumulated metabolites).

Q97. Discuss Urea Cycle Disorders (UCD): the urea cycle, OTC deficiency, the citrulline/orotic acid diagnostic algorithm, and nitrogen scavenger therapy.

The Urea Cycle and Hyperammonemia

The urea cycle is the primary hepatic pathway converting toxic ammonia (from protein/amino acid catabolism) into urea, readily excreted renally — comprising carbamoyl phosphate synthetase I, ornithine transcarbamylase, argininosuccinate synthetase, argininosuccinate lyase, and arginase. A defect at any point impairs ammonia disposal, causing hyperammonemia, which is directly neurotoxic (cerebral edema, progressive encephalopathy via disrupted glutamate metabolism and astrocyte swelling) — a genuinely time-critical emergency category.

OTC Deficiency – The Prototype, Most Common UCD

Ornithine Transcarbamylase (OTC) deficiency is the most common UCD, and distinctively follows X-linked inheritance (unlike other UCD enzyme defects, which are autosomal recessive). Affected males typically present with severe, often neonatal-onset disease, while heterozygous female carriers show highly variable expressivity (asymptomatic to severe, particularly triggered by catabolic stress or the postpartum period), reflecting variable random X-inactivation (lyonization) across hepatocyte populations. Carbamoyl Phosphate Synthetase I (CPS1) deficiency is another important, rarer cause, following autosomal recessive inheritance.

Localizing the Specific Enzymatic Block

Nitrogen Scavenger Therapy

For acute hyperammonemic crisis (following general emergency principles — protein cessation, high-calorie protein-free glucose infusion):

• Sodium Benzoate — conjugates with glycine forming hippurate, renally excreted, removing one nitrogen atom per molecule
• Sodium Phenylacetate/Phenylbutyrate — conjugates with glutamine forming phenylacetylglutamine, removing two nitrogen atoms per molecule (particularly efficient)
• Arginine supplementation — replenishes cycle intermediates for defects distal to arginine-generating steps

Both nitrogen scavenger agents are given as IV infusions during acute crisis (oral formulations for chronic maintenance). Emergency hemodialysis is considered for severe, rapidly rising ammonia not adequately responding to medical therapy, given ammonia's severe, rapidly progressive neurotoxicity.

Q98. Discuss Galactosemia: pathophysiology, classic clinical triad, the E. coli sepsis association, diagnosis, and treatment.

Classic Galactosemia – Pathophysiology

Results from deficiency of Galactose-1-phosphate Uridyltransferase (GALT), the enzyme converting galactose-1-phosphate (generated from dietary lactose) into UDP-galactose. Deficiency causes accumulation of galactose-1-phosphate, exerting direct toxic effects on the liver, kidney, brain, and the developing lens of the eye.

Classic Clinical Triad

• Cataracts — from galactitol accumulation (alternative aldose reductase pathway metabolite) within the lens, causing osmotic damage and the characteristic "oil droplet" appearance — treatable/reversible if identified and dietary treatment started promptly
• Jaundice — hepatocellular dysfunction from direct toxic effects of accumulated galactose-1-phosphate
• Hepatomegaly — progressing, if untreated, to significant hepatic dysfunction/cirrhosis

Diagnosis

Galactosemia is included in most contemporary expanded newborn screening panels (elevated blood galactose or reduced GALT enzyme activity). Confirmatory testing includes direct erythrocyte GALT enzyme activity measurement and, where needed, molecular genetic testing for GALT mutations.

Treatment

Lifelong, strict lactose/galactose-free diet — elimination of all dairy products and other galactose-containing foods, with specialized lactose/galactose-free (typically soy-based or elemental) formula substituted from birth once diagnosis is confirmed or strongly suspected.